Have any questions? 706-721-6582 or cts@augusta.edu
This trial will test an experimental drug called Hu5F9-G4, in combination with standard rituximab, gemcitabine, and oxaliplatin/chemotherapy combination (referred to as R-GemOx). Hu5F9-G4 is a type of protein called an antibody, and it is being tested to see if will help the body's immune system find and destroy cancer cells. The trial will have two phases: Phase 1b will test the safety and tolerability of increasing doses of Hu5F9-G4 in combination with ritixumab. Phase 2 will test Hu5F9-G4 in combination with rituximab to see how effectively it treats indolent lymphoma or diffuse large B-cell lymphoma.